Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lung Neoplasms 84Prostatic Neoplasms 73Leukemia, Myeloid, Acute 73Carcinoma, Non-Small-Cell Lung 61Neoplasm Metastasis 60Breast Neoplasms 56Multiple Myeloma 47Colorectal Neoplasms 47Pancreatic Neoplasms 43Melanoma 36Carcinoma, Renal Cell 36Myelodysplastic Syndromes 35Ovarian Neoplasms 33Leukemia, Lymphocytic, Chronic, B-Cell 30Triple Negative Breast Neoplasms 28Glioblastoma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 25Lymphoma 23Squamous Cell Carcinoma of Head and Neck 22Burkitt Lymphoma 22Fallopian Tube Neoplasms 21Glioma 20Carcinoma, Hepatocellular 20Brain Neoplasms 18Mouth Neoplasms 17Lymphoma, Non-Hodgkin 17Leukemia, Biphenotypic, Acute 17Endometrial Neoplasms 17

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × Specimen Handling × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡